Issue Date: September 1, 2014 | Web Date: August 28, 2014
Roche To Buy Intermune
Roche has agreed to pay $8.3 billion in cash to acquire InterMune. The Brisbane, Calif.-based firm has one product: pirfenidone, a treatment for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It has sold the drug under the name Esbriet in Canada since 2011 and received European authorization in 2012. The drug is awaiting U.S. approval.
The purchase fits Roche’s recent strategy of making bolt-on acquisitions to access promising . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society